Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Sandra M. Swain,Mizuki Nishino,Lisa Lancaster,Bo Li,Andrew G. Nicholson,Brian J. Bartholmai,Jarushka Naidoo,Eva Schumacher-Wulf,Kohei Shitara,Junji Tsurutani,Pierfranco Conte,Terufumi Kato,Fabrice Andre,Charles A. Powell +13 more
TL;DR: In this paper , the authors reviewed characteristics of patients who developed T-DXd-related ILD/pneumonitis and its patterns, produced multidisciplinary guidelines on diagnosis and management, and described areas for future investigation.
read more
About: This article is published in Cancer Treatment Reviews. The article was published on 01 Mar 2022. and is currently open access. The article focuses on the topics: Medicine & Medicine.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Shanu Modi,William Jacot,Hiroji Iwata,Yeon Hee Park,Maria Vidal Losada,Wei Li,Junji Tsurutani,Naoto T. Ueno,Khalil Zaman,Aleix Prat,Konstantinos Papazisis,Hope S. Rugo,Toshinari Yamashita,Nadia Harbeck,Seock-Ah Im,Michelino De Laurentiis,Jean-Yves Pierga,Xiaojia Wang,Andrea Gombos,Eriko Tokunaga,Cecilia Orbegoso Aguilar,Lotus Yung,Feng Xiao,Yingkai Cheng,David Cameron,Shanu Modi,William Jacot,Hiroji Iwata,Yeon Hee Park,Maria Vidal Losada,Wei Li,Junji Tsurutani,Naoto T. Ueno,Khalil Zaman,Aleix Prat,Konstantinos Papazisis,Hope S. Rugo,Toshinari Yamashita,Nadia Harbeck,Seock-Ah Im,Michelino De Laurentiis,Jean-Yves Pierga,Xiaojia Wang,Andrea Gombos,Eriko Tokunaga,Cecilia Orbegoso Aguilar,Lotus Yung,Feng Xiao,Yingkai Cheng,David Cameron +49 more
Abstract: In DESTINY-Breast04 ( NCT03734029 ), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician's choice of chemotherapy (TPC) for patients with human epidermal growth factor receptor 2-low (HER2-low) (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative) metastatic breast cancer. After an extended median follow-up of 32.0 months, median OS in the overall cohort was 22.9 months for T-DXd and 16.8 months for TPC (hazard ratio 0.69; 95% confidence interval 0.55-0.86). For the hormone receptor-positive cohort, median OS was 23.9 and 17.6 months for T-DXd and TPC, respectively (hazard ratio 0.69; 95% confidence interval 0.55-0.87). Median OS also favored T-DXd in exploratory analyses of hormone receptor-negative, estrogen receptor IHC 1%-10% and estrogen receptor IHC >10% cohorts. The overall safety profile of T-DXd was acceptable and generally manageable. Results confirm T-DXd as standard of care after prior chemotherapy in patients with HER2-low metastatic breast cancer. ClinicalTrials.gov identifier: NCT03734029 .
Detection of Drug-induced Interstitial Lung Disease Caused by Cancer Treatment Using Electronic Nose Exhaled Breath Analysis.
I. G. van der Sar,Marlies S. Wijsenbeek,Daphne W Dumoulin,Agnes Jager,Astrid A M van der Veldt,Mariska Rossius,Annemarie C. Dingemans,Catharina C. Moor +7 more
- 25 Mar 2024
TL;DR: This study investigates the use of electronic nose technology to detect drug-induced interstitial lung disease in cancer patients through exhaled breath analysis, potentially improving early diagnosis and treatment outcomes.
References
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis,Ulrich Costabel,David M Hansell,Talmadge E. King,David A. Lynch,Andrew G. Nicholson,Christopher J. Ryerson,Jay H. Ryu,Moisés Selman,Athol U. Wells,Jurgen Behr,Demosthenes Bouros,Kevin K. Brown,Thomas V. Colby,Harold R. Collard,Carlos Robalo Cordeiro,Vincent Cottin,Bruno Crestani,Marjolein Drent,Rosalind F. Dudden,Jim Egan,Kevin R. Flaherty,Cory M. Hogaboam,Yoshikazu Inoue,Takeshi Johkoh,Dong Soon Kim,M Kitaichi,James E. Loyd,Fernando J. Martinez,Jeffrey L. Myers,Shandra Protzko,Ganesh Raghu,Luca Richeldi,Nicola Sverzellati,Jeffrey J. Swigris,Dominique Valeyre +35 more
TL;DR: This update is a supplement to the previous 2002 IIP classification document and outlines advances in the past decade and potential areas for future investigation.
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu,Martine Remy-Jardin,Jeffrey L. Myers,Luca Richeldi,Christopher J. Ryerson,David J. Lederer,Juergen Behr,Vincent Cottin,Sonye K. Danoff,Ferran Morell,Kevin R. Flaherty,Athol U. Wells,Fernando J. Martinez,Arata Azuma,Thomas Bice,Demosthenes Bouros,Kevin K. Brown,Harold R. Collard,Abhijit Duggal,Liam Galvin,Yoshikazu Inoue,R. Gisli Jenkins,Takeshi Johkoh,Ella A. Kazerooni,Masanori Kitaichi,Shandra L Knight,George Mansour,Andrew G. Nicholson,Sudhakar Pipavath,Ivette Buendía-Roldán,Moisés Selman,William D. Travis,Simon L.F. Walsh,Kevin C. Wilson +33 more
TL;DR: The guideline panel provided recommendations related to the diagnosis of IPF, including a conditional recommendation for multidisciplinary discussion and a strong recommendation against measurement of serum biomarkers for the sole purpose of distinguishing IPF from other ILDs.
3.5K
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer,Christina Lacchetti,Bryan J. Schneider,Michael B. Atkins,Kelly J. Brassil,Jeffrey M. Caterino,Ian Chau,Marc S. Ernstoff,Jennifer M. Gardner,Pamela K. Ginex,Sigrun Hallmeyer,Jennifer Holter Chakrabarty,Natasha B. Leighl,Jennifer S. Mammen,David F. McDermott,Aung Naing,Loretta J. Nastoupil,Tanyanika Phillips,Laura Diane Porter,Igor Puzanov,Cristina A. Reichner,Bianca Santomasso,Carole Seigel,Alexander Spira,Maria E. Suarez-Almazor,Yinghong Wang,Jeffrey S. Weber,Jeffrey S. Weber,Jedd D. Wolchok,John A. Thompson +29 more
TL;DR: Recommendations for specific organ system-based toxicity diagnosis and management are presented and, in general, permanent discontinuation of ICPis is recommended with grade 4 toxicities, with the exception of endocrinopathies that have been controlled by hormone replacement.
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J.B.A.G. Haanen,Franck Carbonnel,Caroline Robert,Keith M. Kerr,Solange Peters,James Larkin,K. Jordan +6 more
TL;DR: Calcium, CRP, C-reactive protein, CT, computed tomography, ESR, sedimentation rate, and checkpoint are used to estimate the concentration of phosphorous in the sediments.
2.2K
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Igor Puzanov,Adi Diab,K. Abdallah,Clifton O. Bingham,C. Brogdon,Ramona Dadu,Lamya Hamad,Sang Taek Kim,Mario E. Lacouture,Nicole R. LeBoeuf,D. Lenihan,C. Onofrei,Vickie R. Shannon,Rajeev Sharma,Ann W. Silk,Dimitra Skondra,Maria E. Suarez-Almazor,Yinghong Wang,K. Wiley,Howard L. Kaufman,Marc S. Ernstoff +20 more
TL;DR: A multidisciplinary Toxicity Management Working Group met for a full-day workshop to develop recommendations to standardize management of immune-related adverse events, and presents their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.